S. Tandra, M. M. Yeh, E. M. Brunt, R. Vuppalanchi, O. W. Cummings et al., Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease, J. Hepatol, vol.55, pp.654-659, 2011.

D. E. Amacher, The primary role of hepatic metabolism in idiosyncratic druginduced liver injury, Expert Opin. Drug. Metab. Toxicol, vol.8, pp.335-347, 2012.

M. R. Mcgill, J. , and H. , Animal models of drug-induced liver injury, 2019.

, Biochim. Biophys. Acta Mol. Basis Dis, vol.1865, pp.1031-1039

R. J. Church, H. Wu, M. Mosedale, S. J. Sumner, W. Pathmasiri et al., A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis, Toxicol. Sci, vol.140, pp.481-492, 2014.

J. D. Stewart, R. Horvath, E. Baruffini, I. Ferrero, S. Bulst et al., Polymerase ? gene POLG determines the risk of sodium valproate-induced liver toxicity, Hepatology, vol.52, pp.1791-1796, 2010.

M. I. Lucena, E. García-martín, R. J. Andrade, C. Martínez, C. Stephens et al.,

E. Ulzurrun, M. C. Fernandez, M. Romero-gomez, A. Castiella, R. Planas et al.,

A. M. Dios, C. Guarner, G. Soriano, Y. Borraz, and J. A. Agundez, Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury, Hepatology, vol.52, pp.303-312, 2010.

A. Borgne-sanchez and B. Fromenty, Mitochondrial dysfunction in druginduced liver injury, Drug-Induced Mitochondrial Dysfunction: Progress Towards the Clinics, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01875340

. Hoboken, , pp.49-72